[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100550806":3},{"organization":4,"outcomesModule":7,"designInfo":34,"detailedDescription":40,"studyPopulation":33,"armGroups":41,"interventions":61,"overallOfficials":83,"centralContacts":88,"locations":96,"responsibleParty":230,"collaborators":33,"id":232,"slug":33,"hasResults":233,"nctId":234,"briefTitle":235,"officialTitle":236,"acronym":33,"eligibilityCriteria":237,"healthyVolunteers":233,"sex":238,"minAge":239,"maxAge":33,"enrollmentInfo":240,"targetDuration":33,"studyType":243,"phases":244,"briefSummary":246,"conditions":247,"keywords":249,"overallStatus":99,"whyStopped":33,"lastUpdateSubmitDate":251,"lastUpdatePostDateStruct":252,"startDateStruct":255,"completionDateStruct":257,"leadSponsor":259,"locationsCount":260},{"fullName":5,"class":6},"Guangdong Provincial People's Hospital","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":33},[9],{"measure":10,"description":11,"timeFrame":12},"Composite complete remission (CRc)","composite complete remission，CRc: CR + CRi + MLFS","2 months",[14,18,22,26,29],{"measure":15,"description":16,"timeFrame":17},"the rate of MRD turn negative","minimal residual disease turn negative","6 months",{"measure":19,"description":20,"timeFrame":21},"DoR","Duration of remission","2 year",{"measure":23,"description":24,"timeFrame":25},"RFS","Relapsed-free survival","1 year",{"measure":27,"description":28,"timeFrame":25},"OS","Overall survival",{"measure":30,"description":31,"timeFrame":32},"AE","Incidence of of grade 3-4 adverse events\u002FDuration of severe myelosuppression\u002F Incidence of severe infection\u002FTreatment-related mortality, according to Common Terminology Criteria for Adverse Events, versions 5.0","Throughout the study until the end, up to 2 years",null,{"allocation":35,"interventionModel":36,"interventionModelDescription":33,"primaryPurpose":37,"observationalModel":33,"timePerspective":33,"maskingInfo":38},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":39,"maskingDescription":33,"whoMasked":33},"NONE","Acute myeloid leukemia (AML) is a clonal malignant blood disease with genetic heterogeneity and originated from hematopoietic stem progenitor cells.In the past 50 years, the \"3+7\" induction regimen represented by cytotoxic drugs (including anthracyclines\u002Fanthraquinones combined with cytarabine) has remained the standard induction regimen for newly diagnosed AML patients with intensive chemotherapy. In AML patients \\\u003C60 years old, the \"3+7\" regimen induces a complete response rate of 60% to 80%, but the treatment-related mortality is as high as 13%, and more than half of the patients face the threat of relapse, and the 5-year overall survival rate is about 35% to 40%.",[42,50,57],{"label":43,"type":44,"description":45,"interventionNames":46},"ABC-14 regimen","EXPERIMENTAL","AZA,Venetoclax,Chidamide",[47,48,49],"Drug: Chidamide","Drug: Venetoclax","Drug: azacitidine",{"label":51,"type":52,"description":53,"interventionNames":54},"3+7 chemotherapy regimen","ACTIVE_COMPARATOR","Daunorubicin\u002Fidarubicin\u002Fmitoxantrone and cytarabine",[55,56],"Drug: Anthracyclines or anthraquinones","Drug: cytarabine",{"label":58,"type":52,"description":59,"interventionNames":60},"AB-14 regimen","AZA,Venetoclax",[48,49],[62,67,70,73,80],{"type":63,"name":64,"description":65,"armGroupLabels":66,"otherNames":33},"DRUG","Chidamide","Induction Therapy",[43],{"type":63,"name":68,"description":65,"armGroupLabels":69,"otherNames":33},"Venetoclax",[58,43],{"type":63,"name":71,"description":65,"armGroupLabels":72,"otherNames":33},"azacitidine",[58,43],{"type":63,"name":74,"description":65,"armGroupLabels":75,"otherNames":76},"Anthracyclines or anthraquinones",[51],[77,78,79],"idarubicin","daunorubicin","mitoxantrone",{"type":63,"name":81,"description":65,"armGroupLabels":82,"otherNames":33},"cytarabine",[51],[84],{"name":85,"affiliation":86,"role":87},"Jianyu Weng","Guangdong Provincial People Hosptial","PRINCIPAL_INVESTIGATOR",[89,93],{"name":85,"role":90,"phone":91,"phoneExt":33,"email":92},"CONTACT","020-83827812","wengjianyu@gdph.org.cn",{"name":94,"role":90,"phone":91,"phoneExt":33,"email":95},"Du Xin","xind@gdph.org.cn",[97,113,124,137,145,153,161,169,177,185,196,207,218],{"facility":98,"status":99,"city":100,"state":101,"zip":33,"country":102,"countryCode":103,"cosmosGeoPoint":104,"geoPoint":109,"contacts":110},"Dongguan General Hosptial","RECRUITING","Dongguan","Guangdong","China","CN",{"type":105,"coordinates":106},"Point",[107,108],113.74866,23.01797,{"lat":108,"lon":107},[111],{"name":112,"role":90,"phone":33,"phoneExt":33,"email":33},"yirong Jiang",{"facility":114,"status":99,"city":115,"state":101,"zip":33,"country":102,"countryCode":103,"cosmosGeoPoint":116,"geoPoint":120,"contacts":121},"Foshan First People's Hospital","Foshan",{"type":105,"coordinates":117},[118,119],113.13148,23.02677,{"lat":119,"lon":118},[122],{"name":123,"role":90,"phone":33,"phoneExt":33,"email":33},"Ying Zhao",{"facility":5,"status":99,"city":125,"state":101,"zip":126,"country":102,"countryCode":103,"cosmosGeoPoint":127,"geoPoint":131,"contacts":132},"Guangzhou","510080",{"type":105,"coordinates":128},[129,130],113.25,23.11667,{"lat":130,"lon":129},[133,135],{"name":134,"role":90,"phone":33,"phoneExt":33,"email":33},"Xin Du",{"name":136,"role":90,"phone":33,"phoneExt":33,"email":33},"Jianyu WENG",{"facility":138,"status":99,"city":125,"state":101,"zip":33,"country":102,"countryCode":103,"cosmosGeoPoint":139,"geoPoint":141,"contacts":142},"Sun Yat-sen University Cancer Center",{"type":105,"coordinates":140},[129,130],{"lat":130,"lon":129},[143],{"name":144,"role":90,"phone":33,"phoneExt":33,"email":33},"yang Liang",{"facility":146,"status":99,"city":125,"state":101,"zip":33,"country":102,"countryCode":103,"cosmosGeoPoint":147,"geoPoint":149,"contacts":150},"The Fifth Affiliated Hospital of Guangzhou Medical University",{"type":105,"coordinates":148},[129,130],{"lat":130,"lon":129},[151],{"name":152,"role":90,"phone":33,"phoneExt":33,"email":33},"Runhui Zheng",{"facility":154,"status":99,"city":125,"state":101,"zip":33,"country":102,"countryCode":103,"cosmosGeoPoint":155,"geoPoint":157,"contacts":158},"The First Affiliated Hospital of Guangdong Pharmaceutical University",{"type":105,"coordinates":156},[129,130],{"lat":130,"lon":129},[159],{"name":160,"role":90,"phone":33,"phoneExt":33,"email":33},"xueyi Pan",{"facility":162,"status":99,"city":125,"state":101,"zip":33,"country":102,"countryCode":103,"cosmosGeoPoint":163,"geoPoint":165,"contacts":166},"The First Affiliated Hospital of Guangzhou Medical University",{"type":105,"coordinates":164},[129,130],{"lat":130,"lon":129},[167],{"name":168,"role":90,"phone":33,"phoneExt":33,"email":33},"Zhenqian Huang",{"facility":170,"status":99,"city":125,"state":101,"zip":33,"country":102,"countryCode":103,"cosmosGeoPoint":171,"geoPoint":173,"contacts":174},"The First Affiliated Hospital of Jinan University",{"type":105,"coordinates":172},[129,130],{"lat":130,"lon":129},[175],{"name":176,"role":90,"phone":33,"phoneExt":33,"email":33},"Liye Zhong",{"facility":178,"status":99,"city":125,"state":101,"zip":33,"country":102,"countryCode":103,"cosmosGeoPoint":179,"geoPoint":181,"contacts":182},"The Second Affiliated Hospital of Guangzhou Medical University",{"type":105,"coordinates":180},[129,130],{"lat":130,"lon":129},[183],{"name":184,"role":90,"phone":33,"phoneExt":33,"email":33},"xu Ye",{"facility":186,"status":99,"city":187,"state":101,"zip":33,"country":102,"countryCode":103,"cosmosGeoPoint":188,"geoPoint":192,"contacts":193},"Shenzhen second people's Hospital","Shenzhen",{"type":105,"coordinates":189},[190,191],114.0683,22.54554,{"lat":191,"lon":190},[194],{"name":195,"role":90,"phone":33,"phoneExt":33,"email":33},"xin Du",{"facility":197,"status":99,"city":198,"state":101,"zip":33,"country":102,"countryCode":103,"cosmosGeoPoint":199,"geoPoint":203,"contacts":204},"Affiliated Hospital of Guangdong Medical University","Zhanjiang",{"type":105,"coordinates":200},[201,202],110.38749,21.23391,{"lat":202,"lon":201},[205],{"name":206,"role":90,"phone":33,"phoneExt":33,"email":33},"Yuming ZHANG",{"facility":208,"status":99,"city":209,"state":101,"zip":33,"country":102,"countryCode":103,"cosmosGeoPoint":210,"geoPoint":214,"contacts":215},"Zhuhai General Hosptial","Zhuhai",{"type":105,"coordinates":211},[212,213],113.56778,22.27694,{"lat":213,"lon":212},[216],{"name":217,"role":90,"phone":33,"phoneExt":33,"email":33},"xiaoliang Li",{"facility":219,"status":99,"city":220,"state":221,"zip":33,"country":102,"countryCode":103,"cosmosGeoPoint":222,"geoPoint":226,"contacts":227},"Hainan General Hosptial","Haikou","Hainan",{"type":105,"coordinates":223},[224,225],110.34651,20.03421,{"lat":225,"lon":224},[228],{"name":229,"role":90,"phone":33,"phoneExt":33,"email":33},"Li'e Lin",{"type":231,"investigatorFullName":33,"investigatorTitle":33,"investigatorAffiliation":33,"oldNameTitle":33,"oldOrganization":33},"SPONSOR","100550806",false,"NCT06451861","Randomized Study of ABC-14 Regimen Compared With \"3+7\" Standard Induction Therapy or AB-14 for ND AML","Randomized Study of ABC-14 Regimen ( AZA, Venetoclax and Chidamide) Compared With \"3+7\" Standard Induction Therapy or AB-14 (Venetoclax Combined With Azacitidine) for Newly Diagnosed Acute Myeloid Leukemia","Inclusion Criteria:\n\n1. Diagnosed with AML (the diagnostic criteria refer to WHO2022 standard, non-APL), and have not received systemic anti-leukemia therapy (except hydroxyurea, low-dose cytarabine and other tumor reduction pretreatments);\n2. Age ≥18 years old;\n3. ECOG≤4;\n4. The fertile woman agrees to use effective contraception during the treatment period and up to 3 months after the end of the treatment; Sign the informed consent form.\n\nExclusion Criteria:\n\n1. Known history of allergy to the investigational drug;\n2. Resistance to azacytidine, azacitidine, Venetoclax;\n3. Inability to take oral medication;\n4. Combined with uncontrolled active infections (including bacterial, fungal or viral infections);\n5. Combined with uncontrolled major organ dysfunction: cardiac insufficiency, decompensated liver insufficiency, moderate\u002Fsevere renal insufficiency, etc.;\n6. Participating in other clinical studies that affect the main purpose of this study; Patients deemed unsuitable for participation in this study.","ALL","18 Years",{"count":241,"type":242},240,"ESTIMATED","INTERVENTIONAL",[245],"PHASE2","To compare the efficacy and safty of ABC-14 regimen with the traditional \"3+7\" regimen or AB-14 regimen in the treatment of newly diagnosed acute myeloid leukaemia",[248],"Acute Myeloid Leukemia",[43,250,58],"\"3+7\" regimen","2025-11-14",{"date":253,"type":254},"2025-11-17","ACTUAL",{"date":256,"type":254},"2024-08-21",{"date":258,"type":242},"2027-06-30",{"name":5,"class":6},13]